The Peptide Field. MOTS-c: approval and evidence record.

Editorial review: 2026-07-23. Dataset version: 2026-09-11.1.

https://thepeptidefield.com/peptides/mots-c

Lookup: https://thepeptidefield.com/peptide-evidence-checker?peptide=mots-c#result

This is a dated editorial summary, not a live FDA check or independent medical review. It does not recommend treatment or verify a product in hand.

Status: No FDA-approved MOTS-c drug product

Exact product limits: A substance name and animal findings do not prove that a marketed product is known, safe, or effective. A recognized substance identity and compelling animal biology do not establish the identity, quality, safety, or efficacy of a marketed injectable product.

Human outcomes: Unclear. FDA's 2026 review found no published studies administering MOTS-c drug products to humans.

Body effects in people: Limited. Preclinical metabolic and mitochondrial signals are hypothesis-generating.

What the evidence shows: FDA's current review describes metabolic and bone-related laboratory and animal research. It found no published study in which a MOTS-c drug product was administered to humans.

What remains unknown: There is no established human evidence that a MOTS-c drug product causes weight loss, improves exercise, controls glucose, treats osteoporosis, repairs DNA, or slows aging.

Safety limits: No dosing, injection, sourcing, or performance-use guidance is provided. The absence of human exposure data is a reason for caution, not a blank space to fill with anecdotes.

Approval claim: “A UNII number means MOTS-c is FDA-approved.”
Verdict: Misleading. FDA's substance registry explicitly states that UNII availability does not imply regulatory review or approval.
Evidence basis: Regulatory or product record. Scope: Substance identification versus drug-product approval.
Claim sources: https://precision.fda.gov/uniisearch/srs/unii/A5CV6JFB78

Sources used in the full review (a source is not support for every claim):

U.S. Food and Drug Administration. FDA briefing document for MOTS-c-related bulk drug substances. 2026. Accessed 2026-07-23. https://www.fda.gov/media/193347/download

U.S. Food and Drug Administration Global Substance Registration System. MOTS-c substance record. 2026. Accessed 2026-07-23. https://precision.fda.gov/uniisearch/srs/unii/A5CV6JFB78

U.S. Food and Drug Administration. Bulk drug substances that may present significant safety risks. 2026. Accessed 2026-07-23. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

World Anti-Doping Agency. 2026 Prohibited List. 2026. Accessed 2026-07-23. https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list

Keep the limits, review date, and sources with this record. Check the current source for changes.